OPCU event: Highly Potent Drug Development & Manufacturing

Brian Haney, Senior Director, Global Technical Operations, Curia Global, Inc. discusses how Highly potent compounds (HPAPIs) demand more than standard API capabilities — from containment and cleaning strategies to ensuring safety for operators and product integrity.

At Curia, our high-potency development and manufacturing is supported by SafeBridge®-certified facilities and experienced teams focused on handling cytotoxic and other highly potent compounds.